Grand Pharmaceutical Group Yönetim
Yönetim kriter kontrolleri 3/4
Grand Pharmaceutical Group's CEO is Chao Zhou, appointed in Jun 2021, has a tenure of 3.42 years. total yearly compensation is HK$1.87M, comprised of 90.8% salary and 9.2% bonuses, including company stock and options. directly owns 0.01% of the company’s shares, worth HK$1.62M. The average tenure of the management team and the board of directors is 3.4 years and 3.4 years respectively.
Anahtar bilgiler
Chao Zhou
İcra Kurulu Başkanı
HK$1.9m
Toplam tazminat
CEO maaş yüzdesi | 90.8% |
CEO görev süresi | 3.4yrs |
CEO sahipliği | 0.01% |
Yönetim ortalama görev süresi | 3.4yrs |
Yönetim Kurulu ortalama görev süresi | 3.4yrs |
Son yönetim güncellemeleri
Recent updates
Grand Pharmaceutical Group Limited (HKG:512) Looks Inexpensive But Perhaps Not Attractive Enough
Sep 19Grand Pharmaceutical Group (HKG:512) Is Paying Out A Larger Dividend Than Last Year
Jun 05Market Participants Recognise Grand Pharmaceutical Group Limited's (HKG:512) Earnings
May 22Grand Pharmaceutical Group (HKG:512) Will Pay A Larger Dividend Than Last Year At HK$0.26
Apr 25Grand Pharmaceutical Group (HKG:512) Will Pay A Larger Dividend Than Last Year At HK$0.26
Mar 25We Think Grand Pharmaceutical Group (HKG:512) Can Stay On Top Of Its Debt
Oct 20Here's Why We Think Grand Pharmaceutical Group (HKG:512) Is Well Worth Watching
Sep 26Grand Pharmaceutical Group's (HKG:512) Dividend Will Be Increased To HK$0.14
Jun 04Is Grand Pharmaceutical Group (HKG:512) A Risky Investment?
May 05Grand Pharmaceutical Group (HKG:512) Seems To Use Debt Quite Sensibly
Nov 21Is Grand Pharmaceutical Group Limited (HKG:512) Trading At A 43% Discount?
Sep 05Grand Pharmaceutical Group (HKG:512) Seems To Use Debt Quite Sensibly
Aug 16Here's Why We Think Grand Pharmaceutical Group (HKG:512) Is Well Worth Watching
Jul 28Grand Pharmaceutical Group's (HKG:512) Dividend Will Be HK$0.11
May 29Is Grand Pharmaceutical Group Limited (HKG:512) Trading At A 45% Discount?
Apr 08Grand Pharmaceutical Group (HKG:512) Has A Rock Solid Balance Sheet
Mar 22If You Like EPS Growth Then Check Out Grand Pharmaceutical Group (HKG:512) Before It's Too Late
Jan 24These 4 Measures Indicate That Grand Pharmaceutical Group (HKG:512) Is Using Debt Safely
Dec 13Grand Pharmaceutical Group Limited's (HKG:512) Intrinsic Value Is Potentially 45% Above Its Share Price
Nov 27With EPS Growth And More, China Grand Pharmaceutical and Healthcare Holdings (HKG:512) Is Interesting
Oct 25China Grand Pharmaceutical and Healthcare Holdings (HKG:512) Seems To Use Debt Rather Sparingly
Sep 01Do China Grand Pharmaceutical and Healthcare Holdings's (HKG:512) Earnings Warrant Your Attention?
Jul 12CEO Tazminat Analizi
Tarih | Toplam Tazminat | Maaş | Şirket Kazançları |
---|---|---|---|
Jun 30 2024 | n/a | n/a | HK$2b |
Mar 31 2024 | n/a | n/a | HK$2b |
Dec 31 2023 | HK$2m | HK$2m | HK$2b |
Tazminat ve Piyasa: Chao's total compensation ($USD240.97K) is below average for companies of similar size in the Hong Kong market ($USD496.15K).
Tazminat ve Kazançlar: Insufficient data to compare Chao's compensation with company performance.
CEO
Chao Zhou (34 yo)
3.4yrs
Görev süresi
HK$1,873,000
Tazminat
Mr. Chao Zhou serves as Chief Executive Officer of Grand Pharmaceutical Group Limited (formerly known as China Grand Pharmaceutical and Healthcare Holdings Limited) since June 01, 2021 and serves as its Ex...
Liderlik Ekibi
İsim | Pozisyon | Görev süresi | Tazminat | Sahiplik |
---|---|---|---|---|
Executive Chairman | 3.4yrs | HK$2.89m | 0.021% HK$ 3.3m | |
CEO & Executive Director | 3.4yrs | HK$1.87m | 0.010% HK$ 1.6m | |
Executive Director | 1.4yrs | HK$25.00k | Veri yok | |
Investor Relations Director | no data | Veri yok | Veri yok | |
Executive Director | less than a year | Veri yok | 0.017% HK$ 2.6m | |
Company Secretary | 13.2yrs | Veri yok | Veri yok | |
Chairman of Grand Pharm (China) | no data | Veri yok | Veri yok | |
Vice President | no data | Veri yok | Veri yok |
3.4yrs
Ortalama Görev Süresi
51yo
Ortalama Yaş
Deneyimli Yönetim: 512's management team is considered experienced (3.4 years average tenure).
Yönetim Kurulu Üyeleri
İsim | Pozisyon | Görev süresi | Tazminat | Sahiplik |
---|---|---|---|---|
Executive Chairman | 3.4yrs | HK$2.89m | 0.021% HK$ 3.3m | |
CEO & Executive Director | 1.4yrs | HK$1.87m | 0.010% HK$ 1.6m | |
Executive Director | 1.4yrs | HK$25.00k | Veri yok | |
Executive Director | less than a year | Veri yok | 0.017% HK$ 2.6m | |
Chairman of Grand Pharm (China) | no data | Veri yok | Veri yok | |
Independent Non-Executive Director | 19.7yrs | HK$180.00k | Veri yok | |
Independent Non-Executive Director | 5.9yrs | HK$60.00k | Veri yok | |
Independent Non-Executive Director | 13.5yrs | HK$100.00k | Veri yok | |
Director of Grand Pharm (China) | 30.8yrs | Veri yok | Veri yok | |
Director of Zhejiang Xianju Xianle Pharmaceutical Company Limited | no data | Veri yok | Veri yok | |
Non-Executive Director | less than a year | Veri yok | Veri yok |
3.4yrs
Ortalama Görev Süresi
57yo
Ortalama Yaş
Deneyimli Yönetim Kurulu: 512's board of directors are considered experienced (3.4 years average tenure).